Data from the global multi-centre Phase IIb VANTAGE 095 trial have demonstrated that the histone deacetylase inhibitor, vorinostat, in combination with Velcade is effective in myeloma patients who are considered to be refractory to conventional anti-myeloma treatment. Published recently in Clinical Lymphoma Myeloma & Leukemia, the results showed an objective response rate of 11.3%, median duration of response of 211 days, median overall survival of 11.2 months and a two-year survival rate of 32%. All participants had previously received two or more prior lines of treatment including Velcade and an an immunomodulatory drug. The authors suggest that vorinostat and Velcade may offer a new therapeutic option for this difficult-to-treat patient group.


Read full article